Ledermann, JA; Herd, R; Maraninchi, D; Viens, P; Buclon, M; Philip, T; ... Solid Tumour Working Party Europe,; + view all Ledermann, JA; Herd, R; Maraninchi, D; Viens, P; Buclon, M; Philip, T; Cure, H; Lotz, JP; Chauvin, F; Ferrante, P; Rosti, G; Solid Tumour Working Party Europe,; - view fewer (2001) High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT). ANN ONCOL , 12 (5) 693 - 699.
Full text not available from this repository.
Purpose: to determine the outcome of epithelial ovarian cancer in patients registered with the European Group for Blood and Marrow Transplantation (EBMT).Patients and methods: A retrospective analysis was performed on 254 patients with advanced or recurrent disease, median age 46 years (14-63) from 39 centres treated between 1982 and 1996. Only 25% of patients were known to have no or microscopic disease after initial surgery; in approximately 20% the disease status was unknown, the remainder had macroscopic disease.Results: One hundred five patients received high-dose chemotherapy in complete or very good partial remission, twenty-seven in second remission and the remainder in the presence of residual disease. Most received melphalan or carboplatin, or a combination (86%) supported by autologous bone marrow or peripheral blood stem cells. The survival of patients treated in remission was significantly better than in other groups (median 33 vs. 14 months; P = 0.0001). The durability of remission was longer after transplantation in first remission than in second remission (median disease-free survival 18 vs. 9 months; P = 0.005). With a median follow-up of 76 months from diagnosis the median disease-free and overall survival in stage III disease transplanted in remission is 42 and 59 months and for stage IV disease 26 and 40 months.Conclusions: High-dose chemotherapy has a potential benefit for patients in remission. The results support the conduct of randomised studies to determine whether there is a real value from this treatment.
|Title:||High-dose chemotherapy for ovarian carcinoma: Long-term results from the Solid Tumour Registry of the European Group for Blood and Marrow Transplantation (EBMT)|
|Keywords:||bone marrow transplantation, high-dose chemotherapy, ovarian cancer, ovary cancer, peripheral blood stem-cell transplantation, AUTOLOGOUS TRANSPLANTATION, INTENSITY ANALYSIS, CELL SUPPORT, STAGE-III, CANCER, CARBOPLATIN, CYCLOPHOSPHAMIDE, PACLITAXEL, RESCUE, ESCALATION|
|UCL classification:||UCL > School of Life and Medical Sciences > Faculty of Medical Sciences > Wolfson Institute and Cancer Institute Administration > Cancer Institute > CRUK Cancer Trials Centre|
Archive Staff Only: edit this record